<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05622227</url>
  </required_header>
  <id_info>
    <org_study_id>PekingUMCH-BCa093</org_study_id>
    <nct_id>NCT05622227</nct_id>
  </id_info>
  <brief_title>68Ga PET/CT Imaging in Breast Cancer Patients</brief_title>
  <official_title>68Ga-P16-093 PET/CT Imaging in Primary and Recurrent Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PSMA is highly expressed on the cell surface of the microvasculature of several solid tumors,&#xD;
      including breast cancer. This makes it a potentially imaging target for the detection and&#xD;
      grading of breast cancer. This pilot study was designed to evaluate the diagnostic&#xD;
      performance of 68Ga-P16-093, a novel radiopharmaceutical targeting PSMA, which was compared&#xD;
      with 18F-FDG in the same group of breast cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PSMA has been confirmed to be over expressed in vascular endothelial cells of various&#xD;
      malignant solid tumors, such as breast cancer and renal cancer, which can provide growth&#xD;
      advantages for various cancers by cutting the signal molecules involved in angiogenesis.&#xD;
      Positron emission tomography (PET) imaging using radiolabeled molecules targeting PSMA can&#xD;
      detect a variety of non prostate cancer solid tumors such as breast cancer and glioma.&#xD;
      According to previous studies, PSMA can detect primary and metastasis lesions of breast&#xD;
      cancer patients, and has a higher uptake value in triple negative breast cancer and HER2&#xD;
      overexpressed patients. The uptake may be related to tumor grade.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic performance</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>comparing the number of tumor detected by 68Ga-P16-093 and 18F-FDG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>standardized uptake value (SUV) of tumor</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>comparing the SUVmax of tumor of different lesions derived from 68Ga-P16-093 AND 18F-FDG</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>68Ga-P16-093 and 18F-FDG scan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within 1 week, each patient underwent 68Ga-P16-093 and 18F-FDG PET/CT scan after intravenous administration of 68Ga-P16-093 and 18F-FDG, respectively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Drug: 68Ga-P16-093</intervention_name>
    <description>Intravenous injection of 68Ga-P16-093 with the dosage of 1.5-1.8 MBq (0.04-0.05 mCi)/kg. Tracer doses of 68Ga-P16-093 will be used to image lesions of breast cancer by PET/CT.</description>
    <arm_group_label>68Ga-P16-093 and 18F-FDG scan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  breast cancer patients highly suggested by ultrasound or histologically confirmed;&#xD;
&#xD;
          -  68Ga-P16-093 PET/CT and 18F-FDG within two weeks;&#xD;
&#xD;
          -  signed written consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known allergy against PSMA;&#xD;
&#xD;
          -  any medical condition that in the opinion of the investigator may significantly&#xD;
             interfere with study compliance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhaohui Zhu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xinyu Lu</last_name>
    <phone>86-18813128336</phone>
    <email>lslxysou@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhaohui Zhu</last_name>
    <phone>86-13611093752</phone>
    <email>13611093752@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhaohui Zhu</last_name>
      <phone>86-13611093752</phone>
      <email>13611093752@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 14, 2022</study_first_submitted>
  <study_first_submitted_qc>November 14, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2022</study_first_posted>
  <last_update_submitted>November 14, 2022</last_update_submitted>
  <last_update_submitted_qc>November 14, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

